Dynavax Technologies Corporation, a leading biopharmaceutical company specializing in the development and commercialization of innovative vaccines, is set to present at the upcoming 6th Annual Evercore ISI HealthCONx Conference. Taking place on Tuesday, November 28 at 4:40 p.m. ET, the presentation will be webcast and accessible through the “Events & Presentations” page on Dynavax’s official investors website.
With a focus on protecting the world against infectious diseases, Dynavax has established itself as a notable player in the biopharmaceutical industry. The company boasts two commercial products that have gained regulatory approval in the United States, the European Union, and Great Britain. One of these products is HEPLISAV-B®, a recombinant hepatitis B vaccine that effectively prevents infection caused by all known subtypes of the hepatitis B virus in adults aged 18 and above. The other product is CpG 1018®, a highly versatile adjuvant that is currently employed in several COVID-19 vaccines.
CpG 1018® is not only used in COVID-19 vaccines, but Dynavax is also actively exploring its potential as a premier vaccine adjuvant in other clinical programs. The company is conducting research and development for adjuvanted vaccines targeting shingles and Tdap, and is involved in global collaborations to develop adjuvanted vaccines for conditions such as plague, seasonal influenza, and universal influenza.
To stay up to date with Dynavax’s progress and to learn more about their existing products and development pipeline, interested individuals can visit the company’s official website at www.dynavax.com. Additionally, they can follow Dynavax on LinkedIn and Twitter for regular updates.
FAQ
1. What is Dynavax?
Dynavax is a biopharmaceutical company that specializes in the development and commercialization of innovative vaccines.
2. What products does Dynavax offer?
Dynavax has two commercial products: HEPLISAV-B®, a hepatitis B vaccine for adults, and CpG 1018®, an adjuvant used in multiple COVID-19 vaccines.
3. How can I access Dynavax’s presentation at the Evercore ISI HealthCONx Conference?
The presentation will be webcasted and can be accessed through the “Events & Presentations” page on Dynavax’s official investors website.
4. What other vaccines is Dynavax working on?
Dynavax is actively involved in the development of adjuvanted vaccines for various conditions, including shingles, Tdap, COVID-19, plague, seasonal influenza, and universal influenza.
5. Where can I find more information about Dynavax?
For more information about Dynavax’s products and development pipeline, you can visit their website at www.dynavax.com. You can also follow Dynavax on LinkedIn and Twitter for regular updates.